Gilead partners with insitro for experimental liver meds

Apr 16, 2019

Gilead is partnering with insitro to develop therapies for fatty liver disease non-alcoholic steatohepatitis (NASH), as the recently flunked a key phase 3 NASH trial. The privately held insitro uses machine learning techniques to create large, high-quality data sets to help address problems in the drug discovery and development process.

Gilead is paying insitro $15 million upfront with additional near-term payments up to $35 million based on operational milestones. Gilead also signed a deal with Novo Nordisk for another potential NASH treatment, combining Novo Nordisk’s semaglutide and its own cilofexor and firsocostat.

Read the Reuters report.

Don't miss your Daily Dose.  Subscribe to our eNewsletter here!